Can a vaccine stop lung cancer from outsmarting drugs?
NCT ID NCT05950139
First seen Nov 01, 2025 · Last updated May 11, 2026 · Updated 34 times
Summary
This study tests a cancer peptide vaccine designed to prevent or delay resistance in people with advanced ALK-positive lung cancer who are already on targeted therapy. About 12 participants will receive the vaccine alongside their current medication. The main goals are to check safety and see if the vaccine boosts the immune system's ability to fight the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC STAGE IV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins University
RECRUITINGBaltimore, Maryland, 21287, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.